A Place for Hope

1: Daud AI. Reply to M.-E. Percival et al and L.B. Saltz. J Clin Oncol. 2013 Jul 
1;31(19):2515-6. PubMed PMID: 23967490.

2: Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P,
Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM,
Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC,
Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses
with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul
11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2. PubMed PMID:

3: Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, 
Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S.
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to
effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci
U S A. 2013 Mar 5;110(10):4015-20. doi: 10.1073/pnas.1216013110. Epub 2013 Feb
19. PubMed PMID: 23431193; PubMed Central PMCID: PMC3593920.

4: Daud AI. Removing the unknown from the carcinoma of unknown primary. J Clin
Oncol. 2013 Jan 10;31(2):174-5. doi: 10.1200/JCO.2012.45.7630. Epub 2012 Dec 10. 
PubMed PMID: 23233703.

5: Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I,
Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky
J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf
D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma
metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Lancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub
2012 Oct 8. PubMed PMID: 23051966.

6: Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O,
Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi 
A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A,
Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma
with BRAF V600 mutations. N Engl J Med. 2012 Nov;367(18):1694-703. doi:
10.1056/NEJMoa1210093. Epub 2012 Sep 29. PubMed PMID: 23020132; PubMed Central
PMCID: PMC3549295.

7: Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean
EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull
K, Zacharchuk C, Messersmith WA. Phase I study of bosutinib, a src/abl tyrosine
kinase inhibitor, administered to patients with advanced solid tumors. Clin
Cancer Res. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 
2011 Dec 16. PubMed PMID: 22179664.

8: Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J,
Sondak VK, Messina JL, McCalmont T, Daud AI. Phase I clinical trial of the Src
inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2012
Jan 3;106(1):85-91. doi: 10.1038/bjc.2011.514. Epub 2011 Nov 29. PubMed PMID:
22127285; PubMed Central PMCID: PMC3251861.

9: Daud AI. BEAM trial: lighting the way ahead? J Clin Oncol. 2012 Jan
1;30(1):6-7. doi: 10.1200/JCO.2011.37.5832. Epub 2011 Nov 28. PubMed PMID:

10: Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, 
Huang BY, Tang S, Rhode PR, Wong HC. Phase I trial of ALT-801, an
interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201
complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec
15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12. PubMed
PMID: 21994418.

11: Munster PN, Daud AI. Preclinical and clinical activity of the topoisomerase I
inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs. 2011
Nov;20(11):1565-74. doi: 10.1517/13543784.2011.617740. Review. PubMed PMID:

12: Ahronowitz IZ, Daud AI, Leong SP, Shue EH, Bastian BC, McCalmont TH, Yu SS.
An isolated Merkel cell carcinoma metastasis at a distant cutaneous site
presenting as a second 'primary' tumor. J Cutan Pathol. 2011 Oct;38(10):801-7.
doi: 10.1111/j.1600-0560.2011.01757.x. Epub 2011 Aug 23. PubMed PMID: 21883364.

13: Soon CW, Algazi AP, Cha EN, Daud AI. New horizons in melanoma treatment:
targeting molecular pathways. Ochsner J. 2010 Summer;10(2):93-8. PubMed PMID:
21603363; PubMed Central PMCID: PMC3096197.

14: Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI. NRAS-mutant melanoma: response 
to chemotherapy. Arch Dermatol. 2011 May;147(5):626-7. doi:
10.1001/archdermatol.2011.85. PubMed PMID: 21576590.

15: Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV. Tumor fistulization
associated with targeted therapy: computed tomographic findings and clinical
consequences. J Comput Assist Tomogr. 2011 Jan-Feb;35(1):86-90. doi:
10.1097/RCT.0b013e3181fce2cb. PubMed PMID: 21245693; PubMed Central PMCID:

16: Algazi AP, Soon CW, Daud AI. Treatment of cutaneous melanoma: current
approaches and future prospects. Cancer Manag Res. 2010 Aug 17;2:197-211. doi:
10.2147/CMR.S6073. PubMed PMID: 21188111; PubMed Central PMCID: PMC3004577.

17: DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L,
Hwang J, Weber J, Sondak VK, Daud AI. Phase II trial of sagopilone, a novel
epothilone analog in metastatic melanoma. Br J Cancer. 2010 Nov
9;103(10):1548-53. doi: 10.1038/sj.bjc.6605931. Epub 2010 Oct 5. PubMed PMID:
20924376; PubMed Central PMCID: PMC2990578.

18: Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver
A, Deconti RC, Sondak VK. Pharmacokinetic/pharmacodynamic analysis of adjuvant
pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer
Chemother Pharmacol. 2011 Mar;67(3):657-66. doi: 10.1007/s00280-010-1326-9. Epub 
2010 May 28. PubMed PMID: 20509027; PubMed Central PMCID: PMC3043235.

19: Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central 
nervous system lymphoma. Neurotherapeutics. 2009 Jul;6(3):587-97. doi:
10.1016/j.nurt.2009.04.013. Review. PubMed PMID: 19560747.

20: Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina
JL, Daud AI. Src activation in melanoma and Src inhibitors as therapeutic agents 
in melanoma. Melanoma Res. 2009 Jun;19(3):167-75. doi:
10.1097/CMR.0b013e328304974c. PubMed PMID: 19434004.

21: Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA
3rd, Lush R, Neuger A, Sullivan DM, Munster PN. Potentiation of a topoisomerase I
inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in
melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009 Apr 
1;15(7):2479-87. doi: 10.1158/1078-0432.CCR-08-1931. Epub 2009 Mar 24. PubMed
PMID: 19318485.

22: Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN,
Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I trial of interleukin-12
plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 
Dec 20;26(36):5896-903. doi: 10.1200/JCO.2007.15.6794. Epub 2008 Nov 24. PubMed
PMID: 19029422; PubMed Central PMCID: PMC2645111.

23: Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A,
Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S. Phase I and
pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin
Oncol. 2008 Nov 10;26(32):5198-203. doi: 10.1200/JCO.2008.17.2064. Epub 2008 Sep 
29. PubMed PMID: 18824702.

24: Demierre MF, Sabel MS, Margolin KA, Daud AI, Sondak VK. State of the science 
60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology,
diagnosis, and treatment, as reported in the journal Cancer. Cancer. 2008 Oct
1;113(7 Suppl):1728-43. doi: 10.1002/cncr.23643. Review. PubMed PMID: 18798543.

25: Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. Activated stat-3 in
melanoma. Cancer Control. 2008 Jul;15(3):196-201. PubMed PMID: 18596671.

26: Zager JS, Daud AI. Melanoma: promising new discoveries and treatment
modalities for difficult clinical scenarios. Cancer Control. 2008
Jul;15(3):192-4. PubMed PMID: 18596670.

27: Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK,
Riker AI, Deconti RC, Gabrilovich D. Phenotypic and functional analysis of
dendritic cells and clinical outcome in patients with high-risk melanoma treated 
with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol.
2008 Jul 1;26(19):3235-41. doi: 10.1200/JCO.2007.13.9048. PubMed PMID: 18591558.

28: Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon
VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, 
Glaspy JA, Gomez-Navarro J, Ribas A. Detailed analysis of immunologic effects of 
the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody
tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008
May 1;6:22. doi: 10.1186/1479-5876-6-22. PubMed PMID: 18452610; PubMed Central
PMCID: PMC2412852.

29: Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster
PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud
AI. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly 
in patients with advanced solid malignancies. Clin Cancer Res. 2007 Oct
1;13(19):5855-61. PubMed PMID: 17908979.

30: Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF
inhibitors. Cancer Control. 2007 Jul;14(3):285-94. Review. PubMed PMID: 17615535.

31: Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS,
Sondak VK, Daud AI. Overall and progression-free survival in metastatic melanoma:
analysis of a single-institution database. Cancer Control. 2006 Jul;13(3):211-7. 
PubMed PMID: 16885917.

32: Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy
between topoisomerase II and histone deacetylase inhibitors: predictive
correlates. Mol Cancer Ther. 2005 Dec;4(12):1993-2000. PubMed PMID: 16373714.

33: Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN.
Synergistic interaction between histone deacetylase and topoisomerase II
inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res. 2005 Dec
1;11(23):8467-75. PubMed PMID: 16322310.

34: Riker AI, Jove R, Daud AI. Immunotherapy as part of a multidisciplinary
approach to melanoma treatment. Front Biosci. 2006 Jan 1;11:1-14. Review. PubMed 
PMID: 16146709.

35: Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Valproic acid alters
chromatin structure by regulation of chromatin modulation proteins. Cancer Res.
2005 May 1;65(9):3815-22. PubMed PMID: 15867379.

36: Naing A, Messina JL, Vrionis FR, Daud AI. Uncommon manifestations of common
malignancies: case 3. Malignant melanoma arising from a spinal nerve root. J Clin
Oncol. 2004 Aug 1;22(15):3194-5. PubMed PMID: 15284274.

37: Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN.
Sequence-specific potentiation of topoisomerase II inhibitors by the histone
deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004 May
15;92(2):223-37. PubMed PMID: 15108350.

38: Davies KG, Fargette M, Balla G, Daud AI, Duponnois R, Gowen SR, Mateille T,
Phillips MS, Sawadogo A, Trivino C, Vouyoukalou E, Trudgill DL. Cuticle
heterogeneity as exhibited by Pasteuria spore attachment is not linked to the
phylogeny of parthenogenetic root-knot nematodes (Meloidogyne spp.).
Parasitology. 2001 Jan;122 Pt 1:111-20. PubMed PMID: 11197759.

39: Chandrasekhar S, Münster PN, Henzel WA, Daud AI. Purification and
characterization of a novel 35-kDa protein from transformed cardiomyocytes. Cell 
Biol Int. 1999;23(4):299-306. PubMed PMID: 10600238.

40: Kim KK, Daud AI, Wong SC, Pajak L, Tsai SC, Wang H, Henzel WJ, Field LJ.
Mouse RAD50 has limited epitopic homology to p53 and is expressed in the adult
myocardium. J Biol Chem. 1996 Nov 15;271(46):29255-64. PubMed PMID: 8910585.

41: Soonpaa MH, Daud AI, Koh GY, Klug MG, Kim KK, Wang H, Field LJ. Potential
approaches for myocardial regeneration. Ann N Y Acad Sci. 1995 Mar 27;752:446-54.
Review. PubMed PMID: 7755290.

42: Alho K, Woods DL, Algazi A, Knight RT, Näätänen R. Lesions of frontal cortex 
diminish the auditory mismatch negativity. Electroencephalogr Clin Neurophysiol. 
1994 Nov;91(5):353-62. PubMed PMID: 7525232.

43: Kim KK, Soonpaa MH, Daud AI, Koh GY, Kim JS, Field LJ. Tumor suppressor gene 
expression during normal and pathologic myocardial growth. J Biol Chem. 1994 Sep 
9;269(36):22607-13. PubMed PMID: 8077211.

44: Alho K, Woods DL, Algazi A. Processing of auditory stimuli during auditory
and visual attention as revealed by event-related potentials. Psychophysiology.
1994 Sep;31(5):469-79. PubMed PMID: 7972601.

45: Woods DL, Alho K, Algazi A. Stages of auditory feature conjunction: an
event-related brain potential study. J Exp Psychol Hum Percept Perform. 1994
Feb;20(1):81-94. PubMed PMID: 8133226.

46: Daud AI, Lanson NA Jr, Claycomb WC, Field LJ. Identification of SV40 large
T-antigen-associated proteins in cardiomyocytes from transgenic mice. Am J
Physiol. 1993 May;264(5 Pt 2):H1693-700. PubMed PMID: 8498581.

47: Woods DL, Alho K, Algazi A. Intermodal selective attention: evidence for
processing in tonotopic auditory fields. Psychophysiology. 1993 May;30(3):287-95.
PubMed PMID: 8497558.

48: Katz EB, Steinhelper ME, Delcarpio JB, Daud AI, Claycomb WC, Field LJ.
Cardiomyocyte proliferation in mice expressing alpha-cardiac myosin heavy
chain-SV40 T-antigen transgenes. Am J Physiol. 1992 Jun;262(6 Pt 2):H1867-76.
PubMed PMID: 1377879.

49: Alho K, Woods DL, Algazi A, Näätänen R. Intermodal selective attention. II.
Effects of attentional load on processing of auditory and visual stimuli in
central space. Electroencephalogr Clin Neurophysiol. 1992 May;82(5):356-68.
PubMed PMID: 1374704.

50: Woods DL, Alho K, Algazi A. Intermodal selective attention. I. Effects on
event-related potentials to lateralized auditory and visual stimuli.
Electroencephalogr Clin Neurophysiol. 1992 May;82(5):341-55. PubMed PMID:

51: Woods DL, Alho K, Algazi A. Brain potential signs of feature processing
during auditory selective attention. Neuroreport. 1991 Apr;2(4):189-92. PubMed
PMID: 1893092.

52: Daud AI, Bumpus FM, Husain A. Characterization of angiotensin I-converting
enzyme (ACE)-containing follicles in the rat ovary during the estrous cycle and
effects of ACE inhibitor on ovulation. Endocrinology. 1990 Jun;126(6):2927-35.
PubMed PMID: 2161740.

53: Daud AI, Bumpus FM, Husain A. Evidence for selective expression of
angiotensin II receptors on atretic follicles in the rat ovary: an
autoradiographic study. Endocrinology. 1988 Jun;122(6):2727-34. PubMed PMID:

54: Bumpus FM, Pucell AG, Daud AI, Husain A. Angiotensin II: an intraovarian
regulatory peptide. Am J Med Sci. 1988 Apr;295(4):406-8. Review. PubMed PMID: